I and c/g polymorphisms of the apolipoprotein B gene locus are associated with serum cholesterol and LDL-cholesterol levels in Finland

Perimenopausal women is at risk of atherosclerosis as a result of the increase of LDL cholesterol level and the decrease of HDL cholesterol level. Soy milk powder consumption may protect toward these risk factors. This purpose of study is to investigate the effects of 2x30 g/d soy milk flour for eight weeks on serum cholesterol LDL and HDL levels in hypercholesterolemic perimenopausal women. The 19 subjects received 2x30 g/d soy milk powder for eight weeks. LDL and HDL serum cholesterol levels were determined at 0, 4, 9 weeks. Dietary intakes were assesed using 1x24 hours food recall. Statistical analysis used t Test. After eight weeks intervention, Soy milk powder decreases significant (p0.05) LDL cholesterol levels at the 4th week (8.59±17.31%), and the8th week (7.81±11.32%). Soy milk powder can’t increase HDL cholesterol levels at the 4th and 8th weeks significantly. Soy milk decrease significant the ratio of LDL to HDL (7,03±16,82%) at the 4th week. Consuming soy milk powder 2 x 30 g/d during eight weeks can reduce the LDL cholesterol level and LDL/HDL ratio significantly.

Download Full-text

Abstract 15913: Statin And Ezetimibe in Silent Ambulatory Myocardial Ischemia (SESAMI Trial)

Circulation ◽

10.1161/circ.132.suppl_3.15913 ◽

2015 ◽

Vol 132 (suppl_3) ◽

Author(s):

Waleed Kadro ◽

Maya Turkmani ◽

Hussam Rahim ◽

Oussama Beshir ◽

Oussama Khatib ◽

...

Keyword(s):

Myocardial Ischemia ◽

Statin Therapy ◽

Serum Cholesterol ◽

Ldl Cholesterol ◽

Ambulatory Monitoring ◽

Cholesterol Lowering ◽

Cholesterol Levels ◽

St Segment ◽

Cardiovascular Morbidity And Mortality

Introduction: Cholesterol lowering is associated with a reduction in cardiovascular morbidity and mortality. Statins are the main drugs for cholesterol lowering. Ezetimibe when added to statins gives further reduction in cholesterol but its long-term effect on cardiovascular morbidity and mortality and ischemic events is not known. This study sought to determine whether further cholesterol lowering with ezitimibe will also results in a reduction of myocardial ischemia during daily life. Hypothesis: Further cholestrol with ezetimibe lowering may reduce silent ischemia. Methods: We enrolled 50 patients with proven stable coronary artery disease (CAD) and at least one episode of ST-segment depression on ambulatory ECG monitoring. All of them were receiving optimal therapy for CAD including statin therapy for cholesterol reduction. 25 patients were randomized to continue their statin therapy (Statin only group) and 25 to recieve statin plus Ezitimibe 10mg/day (ezitimibe group). Serum cholesterol and LDL cholesterol levels and ambulatory monitoring were repeated after 4 to 6 months of therapy. The two groups were comparable with respect to baseline characteristics, number of episodes of ST-segment depression, and baseline serum cholesterol levels. Holters were read by a blinded cardiologist. Results: The ezitimibe group had lower mean total and LDL cholesterol levels at study end and experienced a significant reduction in the number of episodes of ST-segment depression compared with the statin only group. ST-segment depression was completely resolved in 13 of 25 patients (52%) in the ezitimibe group versus 3 of 25 (12%) in the statin only group. The ezitimibe group exhibited a highly significant reduction in ambulatory ischemia (P<.001). By logistic regression, treatment with ezitimibe was an independent predictor of ischemia resolution. Conclusions: Further cholesterol lowering with ezitimibe can result in reduction or resolution of myocardial ischemia recorded as episodes of ST-segment depression in ambulatory monitoring of the ECG. A larger study is required to confirm this results. This may be translated into long term mortality reduction for CAD by adding ezetimibe.

Download Full-text